TRACON Pharmaceuticals is a biopharmaceutical company. Co. has a collaboration and clinical trial agreement for the development of envafolimab, an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma in North America. Co. also engages in Santen Pharmaceutical Co. Ltd.'s development of the ophthalmic formulation of carotuximab, called DE-122, for the treatment of wet age-related macular degeneration. Other clinical stage oncology product candidates include: TRC102, which is being developed for the treatment of mesothelioma, lung cancer and solid tumors; and TRC253, which is being developed for the treatment of metastatic castration-resistant prostate cancer. The TCON stock yearly return is shown above.
The yearly return on the TCON stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TCON annual return calculation with any dividends reinvested as applicable (on ex-dates).
|